RYR1 and congenital myopathy: Further studies are needed to define the exact mechanism of the ergogenic effects of these genome-wide epigenetic modifying drugs; nevertheless, our results provide the proof of concept for the development for pharmacological treatment of patients with congenital myopathies linked to recessive RYR1 mutations.